Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona, United States of America.
Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
PLoS Biol. 2024 Jul 31;22(7):e3002673. doi: 10.1371/journal.pbio.3002673. eCollection 2024 Jul.
Development of optimal therapeutics for disease states that can be associated with increased membrane cholesterol requires better molecular understanding of lipid modulation of the drug target. Type 1 cholecystokinin receptor (CCK1R) agonist actions are affected by increased membrane cholesterol, enhancing ligand binding and reducing calcium signaling, while agonist actions of the closely related CCK2R are not. In this work, we identified a set of chimeric human CCK1R/CCK2R mutations that exchange the cholesterol sensitivity of these 2 receptors, providing powerful tools when expressed in CHO and HEK-293 model cell lines to explore mechanisms. Static, low energy, high-resolution structures of the mutant CCK1R constructs, stabilized in complex with G protein, were not substantially different, suggesting that alterations to receptor dynamics were key to altered function. We reveal that cholesterol-dependent dynamic changes in the conformation of the helical bundle of CCK receptors affects both ligand binding at the extracellular surface and G protein coupling at the cytosolic surface, as well as their interrelationships involved in stimulus-response coupling. This provides an ideal setting for potential allosteric modulators to correct the negative impact of membrane cholesterol on CCK1R.
开发可用于治疗与膜胆固醇增加相关疾病状态的最佳疗法,需要更好地了解脂质对药物靶点的调节作用。1 型胆囊收缩素受体(CCK1R)激动剂的作用受到膜胆固醇增加的影响,增强配体结合并减少钙信号传导,而密切相关的 CCK2R 的激动剂作用不受影响。在这项工作中,我们鉴定了一组人 CCK1R/CCK2R 嵌合体突变,这些突变改变了这两种受体对胆固醇的敏感性,为在 CHO 和 HEK-293 模型细胞系中表达时探索机制提供了有力工具。与 G 蛋白稳定结合的突变 CCK1R 构建体的静态、低能量、高分辨率结构没有明显差异,这表明受体动力学的改变是功能改变的关键。我们揭示了 CCK 受体螺旋束构象的胆固醇依赖性动态变化,影响了细胞外表面的配体结合和细胞质表面的 G 蛋白偶联,以及它们在刺激反应偶联中相互关系。这为潜在的变构调节剂提供了理想的环境,可以纠正膜胆固醇对 CCK1R 的负面影响。